DR info

臨床試験数 : 13 / 薬物数 : 14 - (DrugBank : 7) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 75

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

CD19/BCMA CAR T-cells
   Zhejiang University
      2021   Early Phase 1   NCT05263817   China;
Cyclophosphamide
   Chiba University HospitalDepartment of Hematology
      2015   Phase 2   JPRN-UMIN000018385   Japan;
   Sakaida Emiko
      2016   Phase 2   JPRN-jRCTs031180421   Japan;
Daratumumab Injection
   University of Arkansas
      2020   Phase 2   NCT04396496   United States;
Dexamethasone
   Chiba University Graduate School of Medicine
      2015   -   JPRN-UMIN000018660   Japan;
   Mayo Clinic
      2016   Phase 2   NCT02921893   United States;
FPF 300 (thalidomide)
   J-POST Clinical Trial Office
      2012   Phase 3   JPRN-JMA-IIA00084   Japan;
      2010   Phase 2-3   JPRN-JMA-IIA00046   Japan;
G-CSF
   Chiba University HospitalDepartment of Hematology
      2015   Phase 2   JPRN-UMIN000018385   Japan;
Ixazomib Citrate
   Mayo Clinic
      2016   Phase 2   NCT02921893   United States;
Lenalidomide
   ISTITUTO CLINICO HUMANITAS
      2009   -   EUCTR2008-003202-33-IT   Italy;
   Mayo Clinic
      2016   Phase 2   NCT02921893   United States;
Lenalidomide and dexamethasone
   Istituto Clinico Humanitas
      2009   Phase 2   NCT00971685   Italy;
   University Hospital, Limoges
      2012   Phase 2   NCT01639898   France;
Lenalidomide+Dexamethasone
   Chiba University
      2014   Phase 2   NCT02193698   Japan;
Lenalidomide, Dexamethasone
   Peking Union Medical College Hospital
      2014   Phase 2   NCT01816620   China;
Lenograstim
   Sakaida Emiko
      2016   Phase 2   JPRN-jRCTs031180421   Japan;
REVLIMID*21CPS
   ISTITUTO CLINICO HUMANITAS
      2009   -   EUCTR2008-003202-33-IT   Italy;
Thalidomide
   Chiba University Graduate School of Medicine
      2015   -   JPRN-UMIN000018660   Japan;